IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
Authors:
Open Access
- 1 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 904229
Abstract
In this study, we synthesized a molecule GA-1MT (GM) composed of indoleamine 2,3-dioxygenase (IDO) inhibitor (1-methyl-d-tryptophan, 1MT) called NLG8189 and gallic acid (GA) and verified its therapeutic effect on B16F10 melanoma cells and an orthotopic tumor-bearing mouse model. The synthesized molecule GM was analyzed by 1H NMR and mass spectrometry (MS). In addition, we confirmed that GM could mediate the immune response in the B16F10 cell tumor model by flow cytometry and immunofluorescence. The synthesized GM molecule could increase the solubility of 1MT to enhance the drug efficacy and lower costs. Moreover, GM could inhibit melanoma growth by combining 1MT and GA. In vivo experiments showed that GM could effectively inhibit the expression of tyrosinase, regulate the proportion of CD4+ T cells, CD8+ T cells, and regulatory T cells (Treg cells) in tumors, and significantly suppress melanoma growth. The newly synthesized drug GM could more effectively inhibit melanoma than GA and 1MT alone or in combination.Keywords
This publication has 49 references indexed in Scilit:
- c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progressionOncogene, 2011
- Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and RasMelanoma Research, 2011
- Prognostic significance of regulatory T cells in tumorInternational Journal of Cancer, 2010
- Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel NodesJournal of Investigative Dermatology, 2010
- Foxp3 in control of the regulatory T cell lineageNature Immunology, 2007
- Cutaneous Malignant MelanomaMayo Clinic Proceedings, 2006
- Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancerInternational Journal of Cancer, 2006
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004
- Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signallingNature Reviews Cancer, 2004
- Proliferating cell nuclear antigen (PCNA): a dancer with many partnersJournal of Cell Science, 2003